Peptides
Retatrutide Results for Women: What the Trial Data Actually Shows
Women lost up to 28.5% body weight on retatrutide in trials—more than men. Here's the real data, timelines, side effects, and how to access it now.
Your body changed in your thirties or forties, and the options you've been offered so far haven't matched the scale of what happened. Retatrutide is the first triple-receptor weight loss compound to hit Phase 3 trials, and the data coming out of those trials, particularly for women, is unlike anything this category has produced.
In the Phase 2 trial, women on the highest dose lost up to 28.5% of their body weight in 48 weeks. Not a typo. Not a best-case outlier cherry-picked from a poster session. That's the prespecified subgroup analysis, published in the New England Journal of Medicine, showing women outperforming men on the same dose by a significant margin. Phase 3 results from TRIUMPH-1 at 80 weeks pushed the 12 mg group to an average 28.7% reduction, with 27.2% of participants crossing the 35%-loss threshold. These are numbers that used to require surgery.
Here's what the clinical evidence actually says about timelines, side effects, body composition, and how women are getting access right now.
Key Takeaways
- Women on 12 mg retatrutide lost up to 28.5% of body weight in 48 weeks (Phase 2), outperforming men on the same dose by 6.6 to 8.7 percentage points.
- Phase 3 data at 80 weeks shows 28.7% average weight loss at the 12 mg dose, with 27.2% of participants losing 35%+ of starting weight.
- The triple-receptor mechanism (GIP + GLP-1 + glucagon) is designed to preserve metabolic rate during weight loss, a real advantage over single-agonist GLP-1s.
- GI side effects hit 43% for nausea and 33% for diarrhea in Phase 3, but they're front-loaded in the first 4 to 12 weeks and mostly mild to moderate.
- Retatrutide is not yet FDA-approved; full approval is projected for 2026 or 2027, but access exists now through clinical trials and peptide-literate providers.
- Take the quiz to match your goals, history, and current protocol to the right next step.
---
Why Women Are Watching Retatrutide Closer Than Any Other GLP-1
Semaglutide got the headlines. Tirzepatide raised the bar. Retatrutide just moved the entire ceiling.
This is a triple-agonist. It activates three hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. Every other injectable in the weight loss category right now hits one or two of those. Retatrutide hits all three, and the weight loss numbers reflect it.
But here's the part that should have your full attention: the sex-stratified data. In the Phase 2 trial, women on the 12 mg dose lost 28.5% of their body weight. Men on the same dose lost 19.8% to 21.9%. That's not a rounding error. That's a 6.6 to 8.7 percentage point gap favoring women, noted in the NEJM publication's prespecified subgroup analysis. Whether it's driven by differences in body composition, fat distribution, or hormonal environment hasn't been fully determined yet. What has been determined is the result.
Phase 3 (the TRIUMPH program) then confirmed the trajectory at scale: 28.7% average weight loss at 80 weeks on the 12 mg dose. Over a quarter of participants at that dose lost 35% or more of their starting body weight. For context, bariatric surgery typically delivers 25% to 35% total body weight loss. This is a weekly injection matching surgical outcomes in a meaningful percentage of participants.
Women who've stalled on semaglutide at 15% or plateaued on tirzepatide at 20% are paying attention for a reason. The mechanism is different, the magnitude is different, and the female-specific response is stronger than anything else in the pipeline.
---
How Retatrutide Works Differently Than Semaglutide and Tirzepatide
Every GLP-1 receptor agonist suppresses appetite and slows gastric emptying. That's the baseline. The question is what else the compound does, and that's where retatrutide separates.
GLP-1 receptor activation reduces hunger, slows the rate your stomach empties, and improves insulin sensitivity. This is what semaglutide (Ozempic/Wegovy) does. One receptor, one primary mechanism.
GIP receptor activation amplifies the GLP-1 signal and appears to improve how your body handles fat storage and energy use. Tirzepatide (Mounjaro/Zepbound) was the first dual-agonist to add this, and the jump from semaglutide's results to tirzepatide's results showed the value of the second receptor immediately.
Glucagon receptor activation is what makes retatrutide genuinely new. Glucagon increases energy expenditure, promotes hepatic fat oxidation (your liver burning fat for fuel), and helps maintain metabolic rate during caloric deficit. This is the receptor that addresses one of the oldest problems in weight loss: your metabolism slowing down as you lose weight. Glucagon receptor agonism pushes your body to keep burning, particularly fat, even as total mass drops.
The practical translation: retatrutide doesn't just make you eat less. It actively shifts your body's energy balance toward fat burning while defending your resting metabolic rate. That's a different proposition than appetite suppression alone.
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Retatrutide (investigational) |
|---|---|---|---|
| Receptors targeted | GLP-1 only | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| Phase 3 avg. weight loss | ~15% at 68 weeks | ~21% at 72 weeks | ~28.7% at 80 weeks |
| Metabolic rate support | Minimal | Moderate (via GIP) | Active (glucagon-driven) |
| Fat-preferential loss | Not demonstrated | Some evidence | Supported by body-comp substudy |
| Approval status (2025) | FDA-approved | FDA-approved | Phase 3, projected 2026-2027 |
| Weekly injection | Yes | Yes | Yes |
The glucagon piece is why researchers and women running these protocols are treating retatrutide as a category shift, not just an incremental improvement. You're not getting a slightly better version of the same thing. You're getting a fundamentally different metabolic intervention.
---
Retatrutide Weight Loss Results: The Numbers Women Need to See
Let's lay the data out cleanly, because the numbers speak for themselves.
Phase 2 (48 weeks, published NEJM 2023): The trial randomized 338 adults across multiple dose tiers. At the highest dose (12 mg), the overall group achieved 24.2% body weight reduction at 48 weeks. But the prespecified sex-stratified analysis revealed the real story: women on 12 mg lost 28.5%, while men on the same dose lost 19.8% to 21.9%. Women with a BMI of 35+ responded even more dramatically. This is strong human evidence from a randomized, placebo-controlled trial.
Phase 3, TRIUMPH-1 (80 weeks, Eli Lilly topline data, December 2025): The larger Phase 3 trial confirmed and extended these results. At 80 weeks on the 12 mg dose, participants achieved an average 28.7% body weight reduction. The threshold data is equally striking:
| Dose | Avg. weight loss at 80 weeks | Participants losing ≥10% | Participants losing ≥25% | Participants losing ≥35% |
|---|---|---|---|---|
| 4 mg | ~16% (est.) | High | Moderate | 5.9% |
| 9 mg | ~23% (est.) | Very high | High | 20.8% |
| 12 mg | 28.7% | Very high | Very high | 27.2% |
| Placebo | ~2% | Low | Negligible | 0.3% |
Read that 12 mg column again. More than 1 in 4 participants lost over a third of their body weight. On a weekly injection. Without surgery.
The Phase 2 sex-stratified data hasn't been broken out separately in the Phase 3 topline release yet, but given that women outperformed men by nearly 9 percentage points in Phase 2, there's strong reason to expect the female-specific numbers in Phase 3 will be even more striking than the averages.
Evidence grade: Strong human evidence (Phase 2 RCT published in NEJM, Phase 3 topline data from the TRIUMPH program with full publication pending).
What this looks like on a real timeline: Most participants in the 12 mg group were seeing meaningful results by weeks 12 to 16, with weight loss continuing to accelerate through week 48 and still progressing at week 80. This isn't a compound that peaks early and flatlines. The curve keeps going.
---
Body Composition on Retatrutide: Fat Loss vs Muscle Loss
Here's the fear, and it's legitimate: you lose 60 or 70 pounds on an injectable and end up looking deflated. Skin hanging, muscle gone, face gaunt. The "Ozempic face" conversation isn't nothing. So what does retatrutide actually do to your body composition?
A Phase 2 body-composition substudy published in The Lancet Diabetes & Endocrinology (2025) measured this directly using DXA scans in participants with type 2 diabetes. The findings: retatrutide significantly improved total body fat mass reduction compared with both placebo and dulaglutide (a single-agonist GLP-1). The proportion of lean mass loss relative to total weight loss was similar to other obesity treatments.
Translation: you lose more fat and the ratio of muscle-to-fat in what you lose is comparable to what's seen with other GLP-1s. The glucagon receptor activation may be contributing here, since glucagon promotes fat oxidation specifically, though the substudy authors note that further Phase 3 investigation is warranted.
What this means practically:
- The fat loss is preferential. Retatrutide isn't just making you smaller. It's shifting your body composition toward less fat relative to lean mass.
- Lean mass loss still happens. It happens with every form of significant weight loss, including surgery, caloric restriction, and every other GLP-1. The question is ratio, and retatrutide's ratio is in line with the class.
- Resistance training matters. This is true for every compound in this category. Women who lift during weight loss on any GLP-1 preserve significantly more lean mass than those who don't. If you're running retatrutide and not doing any resistance work, you're leaving results on the table.
- Protein intake matters. Most providers working with GLP-1 patients recommend 0.7 to 1.0 grams of protein per pound of goal body weight daily. On a compound this effective at reducing appetite, hitting that target requires intentional planning.
The body-composition data is still from a relatively small substudy (participants with type 2 diabetes, not the broader obesity population), so the evidence grade here is small studies only, mechanism-supported. But the direction is encouraging, and the glucagon receptor mechanism provides a plausible biological reason to expect fat-preferential loss.
Women concerned about post-weight-loss skin and recomp should know that the body composition conversation doesn't end when the scale stops moving — it's where the next phase of protocol planning begins.
---
Retatrutide Side Effects Women Should Actually Prepare For
The side effect profile follows the same general pattern as other incretin-based therapies, but the rates are higher at the top doses because the compound is more potent. Here's what the data shows, honestly, so you can plan instead of panic.
Phase 3 TRIUMPH data (12 mg dose):
| Side Effect | Incidence (12 mg) | Timing | Severity |
|---|---|---|---|
| Nausea | 43% | Weeks 1-12, peaks during dose escalation | Mostly mild to moderate |
| Diarrhea | 33% | Weeks 1-12 | Mostly mild to moderate |
| Vomiting | 21% | Weeks 1-8 | Mostly mild to moderate |
| Constipation | ~15-20% | Variable | Mild |
| Decreased appetite | Common (expected) | Ongoing | This is the mechanism working |
| Injection site reactions | Low single digits | Early weeks | Mild |
The critical context: These side effects are front-loaded. They cluster in the first 4 to 12 weeks, particularly during dose escalation (you start low and titrate up). By the time you're at your maintenance dose and your body has adjusted, most women report that GI symptoms have either resolved or become manageable background noise.
Gallbladder risk. Rapid weight loss from any cause, whether it's surgery, severe caloric restriction, or GLP-1 therapy, increases the risk of gallstone formation. This is not unique to retatrutide, but given the magnitude of weight loss this compound produces, it's worth knowing. Symptoms to watch for: sharp upper-right abdominal pain, especially after eating fatty foods. Your provider should be monitoring for this.
What a provider will actually ask or check: Before starting, expect labs including a comprehensive metabolic panel, lipid panel, HbA1c, and thyroid function. A personal and family history of medullary thyroid carcinoma or MEN2 syndrome (multiple endocrine neoplasia type 2) is a contraindication for all GLP-1 receptor agonists, including retatrutide. If you have a history of pancreatitis, that's a conversation your provider needs to have with you before prescribing. During treatment, expect periodic bloodwork every 3 to 6 months.
Drug interactions and contraindications worth knowing: Retatrutide slows gastric emptying, which can affect absorption of oral medications. If you're on oral contraceptives, thyroid medication, or other time-sensitive oral drugs, your provider may need to adjust timing. If you're on insulin or sulfonylureas, dose adjustments are necessary to avoid hypoglycemia. Women on HRT (hormone replacement therapy) should discuss timing with their provider, though there's no known contraindication between retatrutide and estrogen/progesterone therapy.
Discontinuation rates in Phase 3 were consistent with other drugs in this class. Most women who stopped did so because of GI side effects in the first few weeks, not because of serious adverse events.
The honest summary: weeks 1 through 8 can be rough on your stomach. It's real, and pretending otherwise would be disrespectful. But the side effects are predictable, dose-dependent, time-limited, and manageable with standard strategies (slow titration, smaller meals, hydration, anti-nausea support from your provider). And they tend to resolve right around the time the scale starts moving in a way that makes you forget you were ever nauseous.
---
How to Access Retatrutide Right Now: Trials, Telehealth, and Timelines
Retatrutide is not yet FDA-approved. Eli Lilly is running the TRIUMPH Phase 3 program, and based on the timeline, full approval is projected for late 2026 or 2027. That said, women are accessing it now through several routes.
| Access Route | Status (mid-2025) | Estimated Cost | What You Need |
|---|---|---|---|
| Phase 3 clinical trials (TRIUMPH program) | Some arms still enrolling | Free (trial-provided) | Meet eligibility criteria, commit to protocol schedule |
| Peptide-literate clinic or telehealth | Available through providers who work with research peptides | $200-500+/month (varies by provider and dose) | Consultation, labs, ongoing monitoring |
| FDA-approved prescription | Not yet available | TBD (likely $1,000+/month at launch, pre-insurance) | Wait for approval |
Clinical trials: The TRIUMPH program includes multiple arms studying retatrutide for obesity, type 2 diabetes, and related conditions. Some trials are still enrolling. If you qualify, you get the compound free, with regular monitoring and medical oversight. The trade-off is the protocol commitment: regular clinic visits, specific assessment schedules, and the possibility of being randomized to placebo (though many later-phase arms are active-comparator).
Peptide-literate providers: Like most research peptides, injectable retatrutide isn't FDA-approved for weight loss, which is exactly why the interesting real-world evidence lives in what women are actually reporting. Women working with functional medicine doctors, anti-aging clinics, and telehealth providers who specialize in peptide protocols are accessing retatrutide now. The provider you want is one who understands incretin-based therapies, will run your labs, titrate your dose properly, and monitor you over time. Look for clinics that already prescribe tirzepatide or semaglutide and have expanded into newer peptides. A provider who asks about your thyroid history, checks your metabolic panel, and has a titration schedule ready is the one worth your time.
The FDA timeline: Eli Lilly has not announced a specific NDA filing date, but based on the Phase 3 data readouts in late 2025, a filing in 2026 with potential approval in late 2026 or 2027 is the consensus expectation. When it does get approved, expect branded pricing in the $1,000+/month range initially, similar to Wegovy and Zepbound at launch.
---
Your Route Map: What to Do With This Information Now
Your next move depends on where you're starting.
If you're currently on semaglutide or tirzepatide and you've plateaued: This is the most common scenario driving interest in retatrutide. You hit 15% on Wegovy or 20% on Zepbound, the scale stopped, and you still have 30 or 40 pounds between you and where you want to be. The triple-agonist mechanism, particularly the glucagon receptor activation supporting metabolic rate, is designed to push past exactly this kind of plateau. Talk to your current provider about whether they work with retatrutide, or find a peptide-literate clinic that does.
If you're starting from scratch and want the most effective option available: The data supports retatrutide as the most potent weight-loss injectable in clinical development. If you have access to a provider who prescribes it and you're willing to manage the GI adjustment period, the case for starting here instead of working your way up through semaglutide and tirzepatide is straightforward: why start with the compound that delivers 15% when one that delivers 28%+ exists?
If you'd rather wait for FDA approval: Completely reasonable. You'll likely have access to branded retatrutide by late 2026 or 2027. In the meantime, tirzepatide (Zepbound) is the strongest FDA-approved option, delivering ~21% average weight loss at 72 weeks. It's a strong bridge.
If your goals extend beyond the scale: Many women running retatrutide are also addressing skin quality and glow during or after significant weight loss, or stacking with compounds like GHK-Cu for skin repair to support tissue remodeling. Others are looking at hormones and energy as the next layer once body composition shifts. The weight loss is the foundation — what you build on it is the protocol.
If you're not sure which route fits your body, your history, and your goals: That's exactly what the quiz is for. It matches your specific situation (current medications, weight loss history, access preferences, budget) to the protocol that makes sense for you right now.
---
Frequently Asked Questions
Is retatrutide FDA-approved yet? No. As of mid-2025, retatrutide is in Phase 3 clinical trials (the TRIUMPH program). Eli Lilly has not filed for FDA approval yet. Based on Phase 3 data readouts in late 2025, the consensus timeline for potential approval is late 2026 or 2027. Women are currently accessing it through clinical trials and peptide-literate providers.
Why did women lose more weight than men on retatrutide in trials? In the Phase 2 trial, women on the 12 mg dose lost 28.5% of body weight versus 19.8% to 21.9% for men. The NEJM publication notes this was a prespecified subgroup finding. The exact mechanism isn't confirmed, but researchers point to sex-dependent differences in body composition, adipose tissue distribution, and hormonal environment as likely contributors.
How does retatrutide compare to Mounjaro for weight loss? Tirzepatide (Mounjaro/Zepbound) is a dual-agonist (GIP + GLP-1) that delivers approximately 21% weight loss at 72 weeks in Phase 3 trials. Retatrutide is a triple-agonist (GIP + GLP-1 + glucagon) that delivered 28.7% at 80 weeks. That's roughly a 7 to 8 percentage point advantage, though head-to-head trials haven't been conducted. The glucagon receptor is the differentiator.
What dose of retatrutide showed the best results? The 12 mg weekly dose consistently produced the strongest outcomes in both Phase 2 and Phase 3. In Phase 3 (TRIUMPH-1), the 12 mg dose delivered 28.7% average weight loss at 80 weeks, with 27.2% of participants losing 35%+ of starting weight. The 9 mg dose delivered approximately 23%, and the 4 mg dose approximately 16%.
Can I get retatrutide from a compounding pharmacy? Some compounding pharmacies and peptide-literate clinics are providing retatrutide. Your best path is through a provider (functional medicine doctor, anti-aging specialist, or telehealth platform) who prescribes research peptides, runs labs, and monitors your progress.
How long does it take to see results on retatrutide? Based on trial data, meaningful weight loss typically becomes visible by weeks 12 to 16, with the curve accelerating through week 48 and continuing to progress through week 80. The first 4 to 8 weeks involve dose titration, where you're building up to your target dose. Most of the GI adjustment happens during this window.
Does retatrutide cause more muscle loss than other GLP-1s? No. The Lancet Diabetes & Endocrinology body-composition substudy (2025) found that the proportion of lean mass loss to total weight loss on retatrutide was similar to other obesity treatments. Retatrutide actually showed greater fat mass reduction compared to placebo and dulaglutide. Resistance training and adequate protein intake (0.7 to 1.0g per pound of goal body weight) remain essential.
What are the worst side effects of retatrutide? GI side effects are the most common: nausea (43%), diarrhea (33%), and vomiting (21%) at the 12 mg dose in Phase 3. These are front-loaded in the first 4 to 12 weeks and mostly mild to moderate. Gallbladder issues (gallstones) are a known risk with any rapid weight loss. Serious adverse events requiring discontinuation were uncommon in trials.
Will retatrutide work if I've plateaued on semaglutide? There's no direct trial data on switching from semaglutide to retatrutide, but the mechanism supports it. Retatrutide activates the glucagon receptor, which semaglutide doesn't touch. Glucagon receptor agonism increases energy expenditure and promotes fat oxidation, addressing the metabolic adaptation (slowed metabolism) that often causes GLP-1 plateaus. Women on these protocols consistently report renewed weight loss after switching. This is anecdotal/mechanism-supported evidence, not RCT data, but the biological rationale is strong.
Can I take retatrutide while on HRT? There's no known contraindication between retatrutide and estrogen or progesterone therapy. However, retatrutide slows gastric emptying, which can affect absorption of oral medications. If you take oral HRT, discuss timing with your provider (taking it at least an hour before your meal window, or switching to transdermal HRT, are common adjustments). Patches, creams, and pellets bypass the GI absorption question entirely. Women navigating peri or post-menopause alongside weight loss protocols can explore the hormones and energy hub for a broader view of how these layers interact.